

## BRIEF REPORT

# NITROFURAN RESISTANCE IN *Salmonella enterica* ISOLATED FROM MEAT FOR HUMAN CONSUMPTION

Sandra Martínez-Puchol <sup>1,a</sup>, María J. Pons <sup>2,b</sup>, Lidia Ruiz-Roldán <sup>1,b</sup>,  
Laura Laureano-Adame <sup>3,b</sup>, Alfredo Corujo <sup>3,b</sup>, Theresa J. Ochoa <sup>4,5,c</sup>, Joaquim Ruiz <sup>1,6,b</sup>

<sup>1</sup> Instituto de Salud Global, Hospital Clinic - Universitat de Barcelona, Barcelona, España.

<sup>2</sup> Laboratorio de Microbiología Molecular y Genómica Bacteriana, Universidad Científica del Sur, Lima, Peru.

<sup>3</sup> Nutreco, Toledo, España.

<sup>4</sup> Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

<sup>5</sup> Department of Epidemiology, School of Public Health, University of Texas Health Science Center at Houston, Estados Unidos.

<sup>6</sup> Universidad Continental, Lima, Perú.

<sup>a</sup> Master in Biology; <sup>b</sup> PhD in Biology; <sup>c</sup> medical infectologist, Master in Medicine

## ABSTRACT

The mechanisms of resistance to nitrofurans from 18 meat samples with *Salmonella enterica* (chicken: 15; beef: 2; pork: 1) collected in Lima (Peru) were analyzed. The isolates were serotyped and the susceptibility levels to furazolidone and nitrofurantoin [with and without the efflux pump inhibitor Phenyl-Arginine- $\beta$ -naphthylamide (PA $\beta$ N)], the presence of mutations in the *snrA* and *cnr* genes and the transferability of resistance by conjugation were established. Fifteen samples with *S. infantis* (13 from chicken samples), 2 with *S. enteritidis* and 1 with *S. anatum* were identified. All isolates except the *S. anatum* were resistant to both nitrofurans showing MICs (minimum inhibitory concentration) of furazolidone and nitrofurantoin of 32-64  $\mu$ g/mL and 128-256  $\mu$ g/mL, respectively. The addition of PA $\beta$ N had no effect on the MIC levels. All nitrofuran-resistant isolates showed amino acid codon alterations at both *snrA* and *cnr* (*S. infantis*: *snrA* STOP-151; *cnr* STOP-137; *S. enteritidis*: *snrA* STOP-180; *cnr* STOP-179). No transferable mechanisms of nitrofuran resistance were detected.

**Keywords:** Drug resistance; Furazolidone; Salmonella (source: MeSH NLM).

**Citation:** Martínez-Puchol S, Pons MJ, Ruiz-Roldán L, Laureano-Adame L, Corujo A, Ochoa TJ, et al. Resistencia a nitrofuranos mediada por mutaciones en los genes *cnr* y *snrA* en *Salmonella enterica* procedentes de muestras cárnicas para consumo humano. Rev Peru Med Exp Salud Publica. 2020;37(1):99-103. Doi: <https://doi.org/10.17843/rpmesp.2020.371.4745>

**Correspondence to:** Joaquim Ruiz; Apartado 16, 08214-Badia del Valles, Barcelona, España; [joruiz.trabajo@gmail.com](mailto:joruiz.trabajo@gmail.com)

**Received:** 14/08/2019  
**Approved:** 22/01/2020  
**Online:** 23/03/2020

## INTRODUCTION

Nitrofurans are a group of synthetic antimicrobials which are used against Gram-negative and Gram-positive parasites and bacteria <sup>(1)</sup>. These compounds have been widely used in both human and veterinary medicine, as well as in growth promoters for animals for human consumption <sup>(1)</sup>. However, their use currently in veterinary medicine regarding animals for human consumption is prohibited in many countries because of the risk that these antimicrobials or their metabolites remain in the food <sup>(1)</sup>. Its veterinary use is prohibited in Peru since 2013 <sup>(2)</sup>.

The levels of nitrofuran resistance in Enterobacteriaceae (*Shigella spp.*), cause of diarrhea, are low <sup>(3)</sup>, and the highest levels of resistance to these antimicrobials were reported in *Salmonella spp.* <sup>(4,5)</sup>. Currently, the mechanisms of action of nitrofurans are poorly studied, they have been described mainly in mutants obtained in vitro.

It has been described that nitrofurans need to be activated by nitroreductases to exert their action; the reduction reaction consists of several sequential steps, some of the products generated in the intermediate steps could possess antimicrobial activity<sup>(6,7)</sup>. The nitroreductases involved in these activation processes are NfsA and NfsB<sup>(6)</sup>. Thus, in studies with mutants obtained *in vitro* and in studies developed with clinical isolates<sup>(8-10)</sup>, in *Escherichia coli* the presence of alterations capable of reducing or eliminating the functionality of NfsA and NfsB has been associated with the development of resistance to nitrofurans. The role of efflux pumps in resistance to nitrofurans has also been described. In addition, the OqxAB efflux pumps, which belongs to the RND (Resistance-Nodulation-Division) family, confers resistance to nitrofurantoin<sup>(11)</sup>.

Despite the high levels of resistance in *Salmonella spp.* the number of studies focusing on the mechanisms of resistance to nitrofurans is low<sup>(5,12)</sup>. Therefore, the objective of this study was to determine the levels and mechanisms of resistance to nitrofurantoin in isolates of *Salmonella enterica* from meat samples acquired in traditional markets in Lima.

## THE STUDY

18 samples with *Salmonella enterica* isolated in 2012 from a previous study were used to determine the presence of *Enterobacteriaceae* and levels of *E. coli* antimicrobial resistance in meat samples (pork, chicken or calf) acquired in traditional markets in the north (Comas, San Martin), center (La Victoria, Cercado de Lima) and south (Villa El Salvador) of Lima<sup>(13)</sup>. The study was conducted at ISGlobal, Hospital Clinic - Universitat de Barcelona (Spain), Nutreco (Spain) and Instituto de Medicina Tropical Alexander von Humboldt (Peru). In all cases the isolates were previously identified by biochemical methods and confirmed by amplification of the *invA* gene<sup>(13)</sup>. *S. enterica* isolates were recovered from -80 °C and reconfirmed prior to use by amplification and sequencing of the *16S rRNA* gene<sup>(14)</sup>.

The serotypes of the isolates were determined by means of microarrays (Check & Trace *Salmonella* kit, Check-Points B.V, Wageningen, The Netherlands) following the manufacturer's instructions. Then sensitivity to furazolidone (100 µg) and nitrofurantoin (300 µg) was determined by the disk diffusion method (BD, St. Augustine del Guadalix, Spain), as well as minimum inhibitory concentration (MIC) values by the agar dilution method, following the CLSI (Clinical and Laboratory Standards Institute) guidelines and using *E. coli* ATCC 25922 strain as quality control<sup>(15)</sup>. In the CLSI guide there is no specific cut-off point for furazolidone, so in this case data on MIC and/or halo diameter are reported.

For both nitrofurantoin and furazolidone, MIC values were determined in presence of Phenyl-Arginine-β-Naphthylamide (PAβN), an RND-type efflux pump inhibitor<sup>(8)</sup>. For

## KEY MESSAGES

**Motivation for the study:** Increasing levels of antibiotic resistance in Peru is a serious concern. However, there is a scarcity of data regarding nitrofurantoin resistance in *Salmonella spp.*

**Main findings:** There are high levels of nitrofurantoin resistance in *Salmonella spp.* related with the presence of chromosomal mutations in the *cnr* and *snrA* genes.

**Implications:** Results show the need for systematic investigations of resistance levels to nitrofurans in *Salmonella spp.* mainly aimed at the causes of natural selection of resistant isolates.

its use, PAβN was dissolved in dimethyl sulfoxide (DMSO), which is way it determined the effect of this solvent on bacterial growth.

In all the isolations, *nfsA* and *nfsB* genes were amplified by the polymerase chain reaction (PCR) technique (initial cycle of 94 °C for five minutes, followed by 35 cycles of 94 °C for 40 seconds each, 60 °C for 30 seconds, 68 °C for 40 seconds, and a final extension at 72 °C for five minutes). The PCR was performed with the primers described by Salamanca-Pinzón *et al.*<sup>(16)</sup> and was visualized in 2% agarose gels stained with SYBR Safe (Invitrogen, Carlsbad, USA). The bands obtained were recovered from the gel and purified using the Wizard SV Gel and PCR Clean Up System kit (Promega, Madison, USA). The purified products were sent to Macrogen (Seoul, South Korea) for sequencing.

Finally, the presence of transferable nitrofurantoin resistance mechanisms was determined by conjugation, following the previously described protocol<sup>(17)</sup>. For this purpose, *E. coli* J53 (resistant to sodium azide) was used as the receiving strain and Mueller-Hinton agar supplemented with sodium azide (150 µg/ml) and furazolidone (16 µg/ml) as the medium for selecting the transconjugants.

## RESULTS

The 18 studied isolates came from four markets, different from the three areas included in the original study (northern, central and southern cone) (Table 1), thus demonstrating a wide dissemination throughout the Lima area.

The results of serotyping showed that most of the isolates belonged to the infantis serotype (15 isolates, 83.3%). The remaining three strains were classified as enteritidis (two strains, 11.1%) and anatum (one strain, 5.6%). The isolates of the infantis serotype were recovered from the three types of meat samples, especially from the chicken samples. Thus,

13 of the 15 isolates recovered were from chicken samples, while one of *S. infantis* was isolated from calf samples, and another from pork samples. The two *S. enteritidis* isolates were from chicken samples and the one from *S. anatum* was from calf (Table 1).

All isolates, except for the *S. anatum* strain, had MIC levels of 32-64 µg/ml for furazolidone, being resistant to nitrofurantoin with MICs of 128-256 µg/ml. The isolation of *S. anatum* showed MICs of 8 µg/ml for furazolidone and 32 µg/ml for nitrofurantoin (Table 2).

Correlation between MIC values and halos observed in studies with antibiotic discs was also observed. Thus, the nitrofurantoin resistant isolates showed 8-11 mm diameter halos and 8-13 mm halos for furazolidone, while sensitive isolates showed 20 mm halos for nitrofurantoin and 24 mm halos for furazolidone.

The addition of PAβN did not affect the MIC values, which in all cases remained unchanged, showing no involvement from RND-type efflux pumps in the development of resistance to nitrofurans in the isolates studied. Neither PAβN nor DMSO interfered with the normal growth of the bacteria.

All nitrofurantoin-resistant isolates showed mutations in *snrA* and *cnr*. All 15 *S. infantis* isolates had STOP codons at position 151 of *snrA* and 137 of *cnr*, while the two *S. enteritidis* isolates had STOP codons at positions 180 of *snrA* and 179 of *cnr* (Table 2). Finally, no nitrofurantoin-resistant transconjugants were obtained in the conjugation studies.

## DISCUSSION

Although the use of nitrofurans in animals for human consumption is prohibited in many countries, resistance to them has been described in enteropathogens, such as *Salmonella spp.* isolated from food samples<sup>(4,5)</sup>; in some cases, even traces of nitrofurans have been detected in meat products<sup>(18)</sup>. There are

several possible explanations for these facts, which include the stability of resistance to nitrofurans, the use of these antimicrobials, despite being banned products, or the existence of environmental contamination<sup>(4,8,18)</sup>.

The fact that the enteropathogens isolated originated from samples of the three types of meat (chicken, calf and pork) included in the study and their presence in the different areas of Lima, suggests the wide geographical spread in the country of *S. enterica* resistant to nitrofurans. However, it should be considered that the processed samples were collected in 2012, one year before Peru's ban on the use of nitrofurans in breeding animals for consumption<sup>(2)</sup>.

It has been observed that the acquisition of resistance to nitrofurans is a sequential event, in which the nitro-reductase NfsA and NfsB accumulate alterations that affect their functionality and have an additive effect on the final levels of resistance to nitrofurans<sup>(9)</sup>. The study results were concordant to previous studies, detecting the presence of mutations leading to the presence of STOP codons in the equivalent genes (*snrA* and *cnr*) and the subsequent lack of functional nitroreductases. To date, very few studies have analyzed the mechanisms of resistance to nitrofurans in *S. enterica*; they have found similar scenarios, with the presence of STOP codons or other alterations in the genes *snrA* or *cnr*<sup>(5,12)</sup>.

Although no transconjugants resistant to nitrofurantoin were obtained in this study, transferable mechanisms of resistance to nitrofurantoin have been described. Among these, the OqxAB efflux pump, which has recently been implicated in the development of resistance to nitrofurantoin, deserves special attention<sup>(11)</sup>. OqxAB is an RND-type efflux pump, specific to *Klebsiella spp.* which was first detected and coded in plasmid from *E. coli* of veterinary origin in a study on resistance to olaquinox<sup>(19)</sup>. In Peru, the use of olaquinox in animals intended for human consumption was banned in parallel with the use of nitrofurantoin<sup>(2)</sup>. Currently, at least 14 *oqxA* and 28 *oqxB* alleles are known to be plasmid-coded, but the specific activity of each has not been established<sup>(19)</sup>.

The presence of mutations in *acrB*, *emrD*, *yajR* or *macB*, chromosomal efflux pump coding genes has been implicated in the development of resistance to nitrofurans<sup>(20)</sup>. The most studied of these pumps is AcrAB which, like OqxAB, is an RND-type efflux pump. The AcrAB pump, like other RND pumps including OqxAB, can be inhibited using substances such as PAβN<sup>(19,20)</sup>. In this study, the effect of PAβN was not observed, so it was ruled out that overexpression of AcrAB pumps was involved in the development of nitrofurantoin resistance in these isolates, providing further evidence for the absence of OqxAB plasmid pumps. In a previous study in which furazolidone-resistant *E. coli* mutants were developed, no involvement of PAβN-inhibitable ejection pumps was detected either<sup>(8)</sup>.

Due to the methodology used, the presence of transferable resistance mechanisms which only produced low increases in resistance levels could have gone unnoticed, which is

**Table 1.** Origin of the meat samples

Species	n	Sample	District	Area
<i>S. anatum</i>	1	Calf	Villa el Salvador	South
<i>S. enteritidis</i>	1	Chicken	La Victoria	Center
<i>S. enteritidis</i>	1	Chicken	Villa el Salvador	South
<i>S. infantis</i>	6	Chicken	La Victoria	Center
<i>S. infantis</i>	1	Calf	La Victoria	Center
<i>S. infantis</i>	3	Chicken	Comas	North
<i>S. infantis</i>	2	Chicken	San Martín de Porres	North
<i>S. infantis</i>	2	Chicken	Villa el Salvador	South
<i>S. infantis</i>	1	Pork	Villa el Salvador	South

n: number of *S. enterica* isolates. Only one *Salmonella* isolation per sample was considered.

**Table 2.** Levels and mechanisms of resistance to nitrofurans in *Salmonella* spp.

Serotype	n	Nitrofurantoin			Furazolidone			Substitutions	
		Range (n)	MIC50 <sup>a</sup>	MIC90 <sup>a</sup>	Range (n)	MIC50 <sup>a</sup>	MIC90 <sup>a</sup>	<i>snrA</i>	<i>cnr</i>
<i>S. infantis</i>	15	128 (14) - 256 (1)	128	128	32 (8) - 64 (7)	32	64	STOP-151	STOP-137
<i>S. enteritidis</i>	2	128	-	-	32-64	-	-	STOP-180	STOP-179
<i>S. anatum</i>	1	32	-	-	8	-	-	wt	wt
Total	18	32-256	128	128	8-64	32	32	-	-

n: number of isolates; MIC: minimum inhibitory concentration; wt: without mutation.

<sup>a</sup> Calculated only for *S. infantis*.

a limitation of the present study. Also, the isolates included in the study are from 2012, which highlights the need for carrying out further studies to assess the current situation.

The present study describes the presence of high levels of resistance to nitrofurans in isolates of *Salmonella enterica* from samples of meat foods marketed in Lima. These levels of resistance were directly related to the presence of chromosomal mutations in the *snrA* and *cnr* genes. It is necessary to keep track of the levels of resistance to nitrofurans in *S. enterica*.

**Authorship contributions:** SMP, MJP and JR participated in the conception and design of the article. SMP, MJP, LRR, LLA and

AC participated in the collection of results. SMP, MJP and JR participated in the analysis and interpretation of data. MJP, JR and TJO participated in the writing of the article. All authors conducted the critical review of the article, approved the final version and assumed responsibility for the contents of the manuscript.

**Funding sources:** This work was supported by the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (search for antibiotics and resistant microorganisms in animal feed and in animals for human consumption); JR was supported by the I3 program of the Ministry of Economy and Competitiveness, Spain (grant number: CES11/012). "ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya".

**Conflicts of interest:** All authors have none to declare.

## REFERENCES

- Vass M, Hruska K, Franek M. Nitrofurantoin antibiotics: a review on the application, prohibition and residual analysis. *Vet Med (Praha)*. 2008;53(9):469-500. doi: 10.17221/1979-VETMED
- Carrasco Valiente JA. Prohiben importación y comercialización de diversos principios activos, así como el uso de los mismos en la fabricación de productos veterinarios o alimentos para animales destinados al consumo humano y establecen otras disposiciones. Resolución Directoral N° 0072-2013-MINAGRI-SENASA-DIAIA [Internet]. Diario Oficial El Peruano; 2013 (cited on August 10, 2019): 503464-5. Available at: <https://www.minagri.gob.pe/portal/download/pdf/marcolegal/normaslegales/resolucionesdirectoriales/2013/setiembre/rd72-2013-mi-nagri-senasa-diaia.pdf>
- Pons MJ, Gomes C, Martínez-Puchol S, Ruiz L, Mensa L, Vila J, et al. An-timicrobial resistance in *Shigella* spp. causing traveller's diarrhoea (1995-2010): a retrospective analysis. *Travel Med Infect Dis*. 2013;11(5):315-9. doi: 10.1016/j.tmaid.2013.06.010
- Antunes P, Machado J, Peixe L. Illegal use of nitrofurans in food animals: contribution to human salmonellosis?. *Clin Microbiol Infect*. 2006;12(11):1047-9. doi: 10.1111/j.1469-0691.2006.01539.x
- García V, Montero I, Bances M, Rodicio R, Rodicio MR. Incidence and genetic bases of nitrofurantoin resistance in clinical isolates of two successful multidrug-resistant clones of *Salmonella enterica* serovar Ty-phimurium: pandemic "DT 104" and pUO-StVR2. *Microb Drug Resist*. 2017;23(4):405-12. doi: 10.1089/mdr.2016.0227
- McCalla DR, Kaiser C, Green MHL. Genetics of nitrofurazone resistance in *Escherichia coli*. *J Bacteriol*. 1978;133(1):10-6.
- Peterson FJ, Mason RP, Hovsepian J, Holtzman JL. Oxygen-sensitive and -insensitive nitroreduction by *Escherichia coli* and rat hepatic microsomes. *J Biol Chem*. 1979;254:4009-14.
- Martínez-Puchol S, Gomes C, Pons MJ, Ruiz-Roldán L, Torrents de la Peña A, Ochoa TJ, et al. Development and analysis of furazolidone-resistant *Escherichia coli* mutants. *APMIS*. 2015;123(8):676-81. doi: 10.1111/apm.12401
- Whiteway J, Koziarz P, Veall J, Sandhu N, Kumar P, Hoecher B, et al. Oxygen-insensitive nitroreductases: analysis of the roles of *nfsA* and *nfsB* in development of resistance to 5-nitrofurantoin derivatives in *Escherichia coli*. *J Bacteriol*. 1998;180(21):5529-39.
- Shanmugam D, Esak SB, Narayanaswamy A. Molecular characterization of *nfsA* gene in nitrofurantoin resistant uropathogens. *J Clin Diagn Res*. 2016;10(6):DC05-09. doi: 10.7860/JCDR/2016/17280.7957
- Ho PL, Ng KY, Lo WU, Law PY, Lai EL, Wang Y, et al. Plasmid-mediated OqxAB is an important mechanism for nitrofurantoin resistance in *Escherichia coli*. *Antimicrob Agents Chemother*. 2015;60(1):537-43. doi: 10.1128/AAC.02156-15
- Aviv G, Tsyba K, Steck N, Salmon-Divon M, Cornelius A, Rahav G, et al. A unique megaplasmid contributes to stress tolerance and pathogenicity of an emergent *Salmonella enterica* serovar *Infantis* strain. *Environ Microbiol*. 2014;16(4):977-94. doi: 10.1111/1462-2920.12351
- Ruiz-Roldán L, Martínez-Puchol S, Gomes C, Palma N, Riveros M, Ocampo K, et al. Presencia de Enterobacteriaceae y *Escherichia coli* multirresistente a antimicrobianos en carne adquirida en mercados tradicionales en Lima. *Rev Peru Med Exp Salud Publica*. 2018;35(3):425-32. doi: 10.17843/rpmesp.2018.353.3737.
- Salazar de Vegas EZ, Nieves B, Araque M, Velasco E, Ruiz J, Vila J. Outbreak of infection with *Acinetobacter* strain RUH 1139 in an intensive care unit. *Infect Control Hosp Epidemiol*. 2006;27(4):397-403. doi: 10.1086/503177

15. Clinical Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-eight informational supplement [In-ternet] CLSI document M100-S28. Wayne: CLSI; 2018 [cited on August 11, 2019]. Available at: [https://clsi.org/media/2663/m100ed29\\_sample.pdf](https://clsi.org/media/2663/m100ed29_sample.pdf)
16. Salamanca-Pinzón SG, Camacho-Carranza R, Hernández-Ojeda SL, Frontana-Uribe BA, Espitia-Pinzón CI, Espinosa-Aguirre JJ. Correlation of the genotoxic activation and kinetic properties of *Salmonella enterica* serovar Typhimurium nitroreductases *SnrA* and *cnr* with the redox potentials of nitroaromatic compounds and quinones. *Mutagenesis*. 2010;25(3):249-55. doi: 10.1093/mutage/geq001
17. Pérez-Moreno MO, Pico-Plana E, de Toro M, Grande-Armas J, Quiles-Fortuny V, Pons MJ, *et al.*  $\beta$ -Lactamases, transferable quinolone resistance determinants, and class 1 integron-mediated antimicrobial resistance in human clinical *Salmonella enterica* isolates of non-Typhi-murium serotypes. *Int J Med Microbiol*. 2013;303(1):25-31. doi: 10.1016/j.ijmm.2012.11.003
18. McCracken RJ, Kennedy DG. Furazolidone in chicken: case study of an incident of widespread contamination. *Br Poult Sci*. 2013;54(6):704-12. doi: 10.1080/00071668.2013.850152
19. Ruiz J. Transferable Mechanisms of quinolone resistance from 1998 onward. *Clin Microbiol Rev*. 2019;32(4):e00007-19. doi: 10.1128/CMR.00007-19
20. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev*. 2015;28(2):337-418. doi: 10.1128/CMR.00117-14